The list below, as well as information from Daiichi Sankyo Group-sponsored clinical trials registered and published on registries such as ClinicalTrials.gov, EU-Clinical Trial Register and JapicCTI/jRCT, are provided for informational purposes only, and are not intended to promote any product. Clinical study reports provide results known at the time of the study completion and analysis. Therefore, the results provided may not provide either a complete or current review of the safety and efficacy of the pharmaceutical product studied.
  Health care providers and patients should refer to the current product labeling for detailed information on approved indications in their country or region.
  This information is not intended to replace the advice of a health care professional. Only a physician can determine if a specific medication is the correct or best treatment option for a particular patient. If you have questions, please consult with a health care professional.



Search by Disease Name, Project Code, Generic Name or Study Code


A

Generic Name / Project Code Trade Name Medical Condition Study Code Access to Study Access to Results and Plain Language Summaries
Axicabtagene Ciloleucel YESCARTA® Diffuse Large B-cell Lymphoma; Primary Mediastinal Large B-cell Lymphoma; Transformed Follicular Lymphoma; High Grade B-cell Lymphoma KTEC19-A-J901 jRCT2013210008
Axicabtagene Ciloleucel YESCARTA® Large B Cell Lymphoma KTEC19-A-J201 JapicCTI-183914
Azelnidipine CALBLOCK® Hypertension CB502-021 JapicCTI-050028
AC430 Discontinued Healthy Subjects AC430-001 NCT01287858
AC480IV Discontinued Advanced Solid Cancer AC480IV-001 NCT01245543
ASB17061 Discontinued Atopic Dermatitis ASBI 704 NCT01756898 Tabulated Results (CT.gov)

B

Generic Name / Project Code Trade Name Medical Condition Study Code Access to Study Access to Results and Plain Language Summaries
Baclofen GABALON® Spastic Paralysis DL404-02P JapicCTI-050031 Summary Results (JapicCTI)
Baclofen GABALON® Spastic Paralysis DL404-01 JapicCTI-050061

C

Generic Name / Project Code Trade Name Medical Condition Study Code Access to Study Access to Results and Plain Language Summaries
COVID-19 mRNA Vaccine
(DS-5670)
Prevention of COVID-19 DS5670-A-J101 NCT04821674
jRCT2071200110
Carperitide HANP® Congestive Heart Failure; Myocardiopathies 03-0-162 NCT00259038
Carvedilol ARTIST® Atrial Fibrillation DQ2466-A-J301 JapicCTI-132201 Journal Publication
Colesevelam HCl WELCHOL® Pediatric Type 2 Diabetes Mellitus WEL-A-U307 NCT01258075 Tabulated Results (CT.gov)
Colesevelam HCl WELCHOL® Type 2 Diabetes Mellitus WEL-A-U306 NCT00789750 Tabulated Results (CT.gov)
Colesevelam HCl WELCHOL® Type 2 Diabetes Mellitus WEL-305 NCT00789737 Tabulated Results (CT.gov)
Colesevelam HCl WELCHOL® Hyper-cholesterolemia WEL-407 NCT00755352
Colesevelam HCl WELCHOL® Hyper-cholesterolemia WEL-406 NCT00754507
Colesevelam HCl WELCHOL® Hyper-cholesterolemia; Hyperlipidemia, Familial Combined WEL-403 NCT00754039
Colesevelam HCl WELCHOL® Hyper-cholesterolemia WEL-405 NCT00753779
Colesevelam HCl WELCHOL® Type 2 Diabetes Mellitus; Hyper-cholesterolemia; Pre-diabetes WEL-411 NCT00570739 Tabulated Results (CT.gov)
Colesevelam HCl WELCHOL® Type 2 Diabetes Mellitus WEL-409 NCT00484419 Tabulated Results (CT.gov)
Colesevelam HCl WELCHOL® Type 2 Diabetes Mellitus WEL-202 NCT00361153
Colesevelam HCl WELCHOL® Hyper-cholesterolemia WEL-408 NCT00185107
Colesevelam HCl WELCHOL® Type 2 Diabetes Mellitus WEL-304 NCT00151762
Colesevelam HCl WELCHOL® Type 2 Diabetes Mellitus WEL-302 NCT00151749
Colesevelam HCl WELCHOL® Type 2 Diabetes Mellitus WEL-303 NCT00147758
Colesevelam HCl WELCHOL® Type 2 Diabetes Mellitus WEL-201 NCT00147745 Tabulated Results (CT.gov)
Colesevelam HCl WELCHOL® Type 2 Diabetes Mellitus WEL-301 NCT00147719
Colesevelam HCl WELCHOL® Hyper-cholesterolemia WEL-410 NCT00145574
2005-003511-75
Tabulated Results (CT.gov)
Summary Results (EU-CTIS)
Cevimeline Hydrochloride EVOXAC® Xerostomia CDR0000068698 NCT00017511
CS-0777 Discontinued Multiple Sclerosis CS0777-A-U102 NCT00616733
CS-1036 Discontinued Diabetes CS1036-A-A201 JapicCTI-101069
CS-1036 Discontinued Diabetes CS1036-A-J202 JapicCTI-101121
CS-4771 Discontinued Healthy Subjects CS4771-A-J105 JapicCTI-121939
CS-801 Discontinued Overactive Bladder 150-010 JapicCTI-050025
CS-801 Discontinued Overactive Bladder 150-006 JapicCTI-050026
CS-8080 Discontinued Healthy Subjects CS8080-A-U102 NCT00796575
CS-8080 Discontinued Healthy Subjects CS8080-A-U101 NCT00613431
CS-917 Discontinued Type 2 Diabetes Mellitus CS0917-A-U205 NCT00290940
CS-917 Discontinued Type 2 Diabetes Mellitus CS0917-A-E-107 2004-003195-11 Summary Results (EU-CTIS)

D

Generic Name / Project Code Trade Name Medical Condition Study Code Access to Study Access to Results and Plain Language Summaries
Datopotamab Deruxtecan
(DS-1062)
Non-small Cell Lung Cancer TROPION-LUNG01
DS1062-A-U301
NCT04656652
jRCT2071200104
Datopotamab Deruxtecan
(DS-1062)
Non-small Cell Lung Cancer TROPION-Lung04
DS1062-A-U104
NCT04612751
jRCT2031200449
Datopotamab Deruxtecan
(DS-1062)
Non-small Cell Lung Cancer TROPION-Lung02
DS1062-A-U102
NCT04526691
jRCT2031200193
Datopotamab Deruxtecan
(DS-1062)
Non-small Cell Lung Cancer TROPION-Lung05
DS1062-A-U202
NCT04484142
jRCT2041200097
Datopotamab Deruxtecan
(DS-1062)
Solid Cancer; Non-Small-Cell Lung Cancer; Triple Negative Breast Cancer DS1062-A-J101 NCT03401385
JapicCTI-173812
DS-1001 Glioma DS1001-A-J201 NCT04458272
JapicCTI-205339
DS-1001 Glioma DS1001-A-J101 NCT03030066
JapicCTI-163479
DS-1055 Head and Neck Cancer; Gastric Cancer; Esophageal Cancer; Other Types of Solid Cancer DS1055-A-J101 NCT04419532
JapicCTI-205292
DS-6000 Renal Cancer; Ovarian Cancer DS6000-A-U101 NCT04707248
DS-6016 Healthy Subjects DS6016-A-J101 NCT04818398
jRCT2051200155
DS-6157 Gastrointestinal Stromal Tumor DS6157-A-U101 NCT04276415
JapicCTI-205184
DS-7300 Advanced Solid Cancer DS7300-A-J101 NCT04145622
JapicCTI-194992
Denosumab PRALIA® Rheumatoid Arthritis AMG162-D-J301 NCT01973569
JapicCTI-132277
Tabulated Results (CT.gov)
Summary Results (JapicCTI)
Denosumab RANMARK® Multiple Myeloma 20090482 JapicCTI-121876 Summary Results (JapicCTI)
Denosumab RANMARK® Bone Metastases 20110113 JapicCTI-121868 Summary Results (JapicCTI)
Denosumab RANMARK® Giant Cell Tumor of Bone AMG162-B-J201 JapicCTI-111665 Journal Publication
Denosumab PRALIA® Rheumatoid Arthritis AMG162-D-J201 JapicCTI-101263 Summary Results (JapicCTI)
Denosumab RANMARK® Breast Cancer 20060359 JapicCTI-101163 Summary Results (JapicCTI)
Denosumab RANMARK® Breast Cancer 20050136 JapicCTI-090906 Journal Publication
Denosumab PRALIA® Osteoporosis AMG162-A-J301 NCT00680953
JapicCTI-090797
Tabulated Results (CT.gov)
Journal Publication
Journal Publication
Diphtheria Pertussis Tetanus Combined Vaccine Adsorbed Diphtheria-purified Pertussis-tetanus Combined Vaccine  Prevention of Diphtheria; Tetanus; Pertussis VN0103-A-J301 JapicCTI-142535  
DS-1205 Out-licensed Non-small Cell Lung Cancer DS1205-A-J102 NCT03599518
JapicCTI-184026
DS-1205 Out-licensed Non-small Cell Lung Cancer DS1205-A-U101 NCT03255083
2017-000542-21
DS-6051 Out-licensed Advanced Solid Malignant Tumors DS6051-A-J102 NCT02675491
JapicCTI-153111
DJ-927 Discontinued Colorectal Cancer CDR0000356034 NCT00080834
DJ-927 Discontinued Solid Cancer CDR0000346368 NCT00077077
DJ-927 Discontinued Non-small Cell Lung Cancer 927E-PRT007 2004-000696-34 Summary Results (EU-CTIS)
DS-1040 Discontinued Acute Ischemic Stroke DS1040-A-U103 NCT02586233
2015-001824-43
Tabulated Results (CT.gov)
DS-1040 Discontinued Acute Submassive Pulmonary Embolism DS1040-B-U107 NCT02923115
2015-005211-32
Tabulated Results (CT.gov)
DS-1040 Discontinued Acute Ischemic Stroke DS1040-A-J110 NCT03198715
JapicCTI-173612
Tabulated Results (CT.gov)
Summary Results (JapicCTI)
DS-1040 Discontinued Healthy Subjects DS1040-A-E108 NCT02647307
2015-003470-32
DS-1040 Discontinued Healthy Subjects DS1040-A-E106 NCT02560688
2015-003018-26
DS-1040 Discontinued Acute Ischemic Stroke DS1040-A-E102 NCT02071004
DS-1093 Discontinued Healthy Subjects DS1093-A-E102 NCT02142400
2014-000552-28
DS-1093 Discontinued Kidney Disease DS1093-A-E103 NCT02299661
2014-002331-33
DS-1123 Discontinued Advanced Solid Tumours DS1123-A-J101 NCT02690337
JapicCTI-153085
DS-1150 Discontinued Type 2 Diabetes Mellitus DS1150-A-U101 NCT02004678
DS-1971 Discontinued Healthy Subjects DS1971-A-E106 NCT02564861
2015-002885-22
DS-1971 Discontinued Type 2 Diabetes Mellitus; Neuropathic Pain DS1971-A-U202 NCT02673866
DS-1971 Discontinued Healthy Subjects DS1971-A-E105 NCT02473627
2015-000330-30
DS-1971 Discontinued Pain DS1971-A-J201 JapicCTI-163193
DS-1971 Discontinued Healthy Subjects DS1971-A-E104 NCT02266940
2014-003662-24
DS-1971 Discontinued Healthy Subjects DS1971-A-E103 NCT02261376
2014-003019-13
DS-1971 Discontinued Healthy Subjects DS1971-A-E102 NCT02190058
2014-001800-23
DS-1971 Discontinued Healthy Subjects DS1971-A-E101 NCT02107885
2014-000240-15
DS-2248 Discontinued Solid Cancer DS2248-A-U101 NCT01288430
2011-002666-21
Tabulated Results (CT.gov)
DS-2330 Discontinued Chronic Hemodialysis DS2330-A-U103 NCT03305471
DS-2741 Discontinued Atopic Dermatitis;
Healthy Subjects
DS2741-A-J101 NCT04211415
JapicCTI-195071
DS-3078 Discontinued Solid Cancer; Lymphomas DS3078-A-U101 NCT01588678
2011-005988-24
DS-5573 Discontinued Advanced Solid Malignant Tumors DS5573-A-J101 NCT02192567
JapicCTI-142586
DS-7080 Discontinued Macular Degeneration DS7080-A-U101 NCT02530918
DS-7250 Discontinued Diabetes DS7250-A-J201 JapicCTI-121963
DS-7309 Discontinued Type 2 Diabetes Mellitus DS7309-A-U102 NCT01956305
DS-7309 Discontinued Type 2 Diabetes Mellitus DS7309-A-U101 NCT01862939
DS-7423 Discontinued Solid Cancer; Colorectal Cancer; Endometrial Cancer DS7423-A-U101 NCT01364844
DS-7423 Discontinued Solid Cancer DS7423-A-J102 JapicCTI-121766
DS-8273 Discontinued Advanced Colorectal Cancer DS8273-A-U103 NCT02991196
DS-8273 Discontinued Advanced Solid Cancer; Lymphomas DS8273-A-U101 NCT02076451
DS-8500 Discontinued Type 2 Diabetes Mellitus DS8500-A-J204 NCT02685345
JapicCTI-163136
DS-8500 Discontinued Hepatic or Renal Impairment DS8500-A-J107 JapicCTI-163135
DS-8500 Discontinued Type 2 Diabetes Mellitus DS8500-A-J205 NCT02669732
JapicCTI-163126
DS-8500 Discontinued Type 2 Diabetes Mellitus DS8500-A-J203 NCT02628392
JapicCTI-153068
DS-8500 Discontinued Type 2 Diabetes Mellitus DS8500-A-U202 NCT02647320 Tabulated Results (CT.gov)
DS-8500 Discontinued Type 2 Diabetes Mellitus DS8500-A-J201 NCT02222350
JapicCTI-142597
DS-8500 Discontinued Healthy Subjects DS8500-A-J103 JapicCTI-173550
DS-8500 Discontinued Healthy Subjects DS8500-A-J108 JapicCTI-163233
DS-8500 Discontinued Healthy Subjects DS8500-A-J110 JapicCTI-163299
DS-8500 Discontinued Healthy Subjects DS8500-A-U105 NCT03699774
DS-8500 Discontinued Healthy Subjects DS8500-A-U112 NCT02790684
DS-8500 Discontinued Healthy Subjects DS8500-A-U109 NCT02790671
DS-8500 Discontinued Healthy Subjects DS8500-A-J106 JapicCTI-152878
DS-8500 Discontinued Healthy Subjects DS8500-A-J104 JapicCTI-142673
DS-8895 Discontinued Advanced Solid Cancer DS8895-A-J101 NCT02004717
JapicCTI-132306
DS-9231 (TS23) Discontinued Acute Pulmonary Embolism DS9231-A-U201 2017-000552-25

E

Generic Name / Project Code Trade Name Medical Condition Study Code Access to Study Access to Results and Plain Language Summaries
Edoxaban
(DU-176b)
SAVAYSA®; LIXIANA® Non-valvular Atrial Fibrillation DSCN-ETNA AF-RWS-001 NCT04747496
Edoxaban
(DU-176b)
SAVAYSA®; LIXIANA® Atrial Fibrillation ETAF-TR-01 NCT04594915
Edoxaban
(DU-176b)
SAVAYSA®; LIXIANA® Non-valvular Atrial Fibrillation DS-EDO-01-20-DE NCT04519944
Edoxaban
(DU-176b)
SAVAYSA®; LIXIANA® Cardiac Disease DU176b-C-U313 NCT03395639
2017-000475-90
Edoxaban
(DU-176b)
SAVAYSA®; LIXIANA® Atrial Fibrillation DU176b-C-A4012 NCT03247582
Edoxaban
(DU-176b)
SAVAYSA®; LIXIANA® Atrial Fibrillation DU176b-C-A4011 NCT03247569
Edoxaban
(DU-176b)
SAVAYSA®; LIXIANA® Venous Thromboembolism DU176b-D-A4010 NCT02952599
Edoxaban
(DU-176b)
SAVAYSA®; LIXIANA® Non-Valvular Atrial Fibrillation DU176b-C-A4008 NCT02951039
Edoxaban
(DU-176b)
SAVAYSA®; LIXIANA® Non-Valvular Atrial Fibrillation DU176B-C-U4001 NCT02943785
2016-003930-26
Edoxaban
(DU-176b)
SAVAYSA®; LIXIANA® Atrial Fibrillation; Venous Thromboembolism DSE-EDO-02-15-EU NCT02950168
Edoxaban
(DU-176b)
SAVAYSA®; LIXIANA® Non-Valvular Atrial Fibrillation DU176b-C-E314 NCT02964949
2016-001795-30
Tabulated Results (EU-CTIS)
Edoxaban
(DU-176b)
SAVAYSA®; LIXIANA® Venous Thromboembolism DSE-EDO-05-14-EU NCT02943993
Edoxaban
(DU-176b)
SAVAYSA®; LIXIANA® Non Valvular Atrial Fibrillation DSE-EDO-04-14-EU NCT02944019
Edoxaban
(DU-176b)
SAVAYSA®; LIXIANA® Atrial Fibrillation DSE-EDO-01-16-EU NCT02942576
2016-003069-25
Tabulated Results (CT.gov)
Tabulated Results (EU-CTIS)
Edoxaban
(DU-176b)
SAVAYSA®; LIXIANA® Non-Valvular Atrial Fibrillation DSE-EDO-01-15-EU NCT02866175
2016-002683-14
Tabulated Results (CT.gov)
Tabulated Results (EU-CTIS)
Edoxaban
(DU-176b)
SAVAYSA®; LIXIANA® Non-valvular Atrial Fibrillation DU176b-C-J316 NCT02801669
JapicCTI-163266
Tabulated Results (CT.gov)
Summary Results (JapicCTI)
Edoxaban
(DU-176b)
SAVAYSA®; LIXIANA® Venous Thromboembolism DU176b-D-U312 NCT02798471
2016-000991-49
Edoxaban
(DU-176b)
SAVAYSA®; LIXIANA® Deep Vein Thrombosis; Venous Thromboembolism DU176b-A-U157 NCT02303431
2015-005732-18
Edoxaban
(DU-176b)
SAVAYSA®; LIXIANA® Venous Thromboembolism; Deep Vein Thrombosis; Pulmonary Embolism; Cancer DU176b-D-U311 NCT02073682
2014-004708-30
Tabulated Results (CT.gov)
Tabulated Results (EU-CTIS)
Edoxaban
(DU-176b)
SAVAYSA®; LIXIANA® Atrial Fibrillation DU176b-F-E308 NCT02072434
2013-003148-21
Tabulated Results (EU-CTIS)
Edoxaban
(DU-176b)
SAVAYSA®; LIXIANA® Peripheral Arterial Disease DU176b-E-U210 NCT01802775
2012-003009-88
Tabulated Results (CT.gov)
Tabulated Results (EU-CTIS)
Edoxaban
(DU-176b)
SAVAYSA®; LIXIANA® Non-valvular Atrial Fibrillation DU176b-C-J307 JapicCTI-111716 Summary Results (JapicCTI)
Edoxaban
(DU-176b)
SAVAYSA®; LIXIANA® Atrial Fibrillation DU176b-B-J307 NCT01857622 Tabulated Results (CT.gov)
Edoxaban
(DU-176b)
SAVAYSA®; LIXIANA® Venous Thromboembolism DU176b-B-J306 NCT01857583 Tabulated Results (CT.gov)
Edoxaban
(DU-176b)
SAVAYSA®; LIXIANA® Non-Valvular Atrial Fibrillation DU176b-D-U211 NCT01662908 Tabulated Results (CT.gov)
Edoxaban
(DU-176b)
SAVAYSA®; LIXIANA® Venous Thromboembolism; Thromboembolism; Thrombosis; Deep Vein Thrombosis; Arthroplasty; Hip Replacement DU176b-B-J209 NCT01203098
JapicCTI-090827
Tabulated Results (CT.gov)
Summary Results (JapicCTI)
Edoxaban
(DU-176b)
SAVAYSA®; LIXIANA® Deep-Vein Blood Clots; Lung Blood Clots DU176b-D-U305 NCT00986154
2009-014290-40
JapicCTI-101043
Tabulated Results (CT.gov)
Summary Results (EU-CTIS)
Edoxaban
(DU-176b)
SAVAYSA®; LIXIANA® Venous Thromboembolism DU176b-B-J304 NCT01181167
JapicCTI-090771
Tabulated Results (CT.gov)
Summary Results (JapicCTI)
Edoxaban
(DU-176b)
SAVAYSA®; LIXIANA® Venous Thromboembolism DU176b-B-J303 NCT01181141
JapicCTI-090798
Tabulated Results (CT.gov)
Journal Publication
Edoxaban
(DU-176b)
SAVAYSA®; LIXIANA® Venous Thromboembolism DU176b-B-J302 NCT01181102
JapicCTI-090727
Tabulated Results (CT.gov)
Summary Results (JapicCTI)
Edoxaban
(DU-176b)
SAVAYSA®; LIXIANA® Atrial Fibrillation DU176b-C-U301 NCT00781391
2008-004522-16
JapicCTI-090775
Tabulated Results (CT.gov)
Summary Results (EU-CTIS)
Journal Publication
Edoxaban
(DU-176b)
SAVAYSA®; LIXIANA® Atrial Fibrillation DU176b-C-J225 NCT00829933
JapicCTI-070391
Tabulated Results (CT.gov)
Edoxaban
(DU-176b)
SAVAYSA®; LIXIANA® Atrial Fibrillation DU176b-C-J226 NCT00806624 Tabulated Results (CT.gov)
Edoxaban
(DU-176b)
SAVAYSA®; LIXIANA® Venous Thromboembolism DU176b-04 NCT01203072
JapicCTI-060283
Tabulated Results (CT.gov)
Summary Results (JapicCTI)
Edoxaban
(DU-176b)
SAVAYSA®; LIXIANA® Atrial Fibrillation DU176b-PRT018 NCT00504556
2007-001271-11
Tabulated Results (CT.gov)
Summary Results (EU-CTIS)
Edoxaban
(DU-176b)
SAVAYSA®; LIXIANA® Thrombosis; Hip Replacement DU176b-PRT011 NCT00398216
2006-000758-29
Tabulated Results (CT.gov)
Summary Results (EU-CTIS)
Edoxaban
(DU-176b)
SAVAYSA®; LIXIANA® Arthroplasty, Hip Replacement; Thrombosis DU176b-PRT007 NCT00107900
2004-004415-29
Tabulated Results (CT.gov)
Summary Results (EU-CTIS)
Edoxaban
(DU-176b)
SAVAYSA®; LIXIANA® Healthy Subjects DU176b-A-U158 NCT02047565
Esaxerenone
(CS-3150)
MINNEBRO® Type 2 Diabetes CS3150-B-J309 JapicCTI-173696 Summary Results (JapicCTI)
Esaxerenone
(CS-3150)
MINNEBRO® Type 2 Diabetes CS3150-B-J308 JapicCTI-173695 Summary Results (JapicCTI)
Esaxerenone
(CS-3150)
MINNEBRO® Type 2 Diabetes Mellitus CS3150-B-J204 NCT02345057
JapicCTI-152774
Esaxerenone
(CS-3150)
MINNEBRO® Diabetes CS3150-B-J202 JapicCTI-122018
Esaxerenone
(CS-3150)
MINNEBRO® Primary Aldosteronism CS3150-A-J307 NCT02885662
JapicCTI-163349
Summary Results (JapicCTI)
Esaxerenone
(CS-3150)
MINNEBRO® Essential Hypertension CS3150-A-J303 NCT02848170
JapicCTI-163324
Summary Results (JapicCTI)
Esaxerenone
(CS-3150)
MINNEBRO® Hypertension With Type 2 Diabetes and Albuminuria CS3150-A-J306 NCT02807974
JapicCTI-163293
Summary Results (JapicCTI)
Esaxerenone
(CS-3150)
MINNEBRO® Severe Hypertension CS3150-A-J304 NCT02808026
JapicCTI-163287
Summary Results (JapicCTI)
Esaxerenone
(CS-3150)
MINNEBRO® Moderate Renal Impairment; Hypertension CS3150-A-J305 NCT02807987
JapicCTI-163288
Summary Results (JapicCTI)
Esaxerenone
(CS-3150)
MINNEBRO® Essential Hypertension CS3150-A-J301 NCT02890173
JapicCTI-163348
Summary Results (JapicCTI)
Esaxerenone
(CS-3150)
MINNEBRO® Essential Hypertension CS3150-A-J302 NCT02722265
JapicCTI-163176
Summary Results (JapicCTI)
Esaxerenone
(CS-3150)
MINNEBRO® Hypertension; Moderate Renal Impairment CS3150-A-J206 NCT02448628
JapicCTI-152883
Summary Results (JapicCTI)
Esaxerenone
(CS-3150)
MINNEBRO® Hypertension CS3150-A-J203 NCT02345044
JapicCTI-152772
Summary Results (JapicCTI)
Esaxerenone
(CS-3150)
MINNEBRO® Hypertension CS3150-A-J201 JapicCTI-121921 Summary Results (JapicCTI)
Esaxerenone
(CS-3150)
MINNEBRO® Hepatic Impairment CS3150-A-J109 JapicCTI-163339 Summary Results (JapicCTI)
Esaxerenone
(CS-3150)
MINNEBRO® Healthy Subjects CS3150-A-U106 NCT04019652
Esaxerenone
(CS-3150)
MINNEBRO® Healthy Subjects CS3150-C-J101 JapicCTI-194837
Esaxerenone
(CS-3150)
MINNEBRO® Healthy Subjects CS3150-A-J108 JapicCTI-163286 Summary Results (JapicCTI)
Esaxerenone
(CS-3150)
MINNEBRO® Healthy Subjects CS3150-A-J110 JapicCTI-163379 Summary Results (JapicCTI)
Esaxerenone
(CS-3150)
MINNEBRO® Healthy Subjects CS3150-A-J111 JapicCTI-163443 Summary Results (JapicCTI)
Esaxerenone
(CS-3150)
MINNEBRO® Healthy Subjects CS3150-A-J112 JapicCTI-163452 Summary Results (JapicCTI)
Esaxerenone
(CS-3150)
MINNEBRO® Healthy Subjects CS3150-A-J102 JapicCTI-163476 Summary Results (JapicCTI)
Esaxerenone
(CS-3150)
MINNEBRO® Healthy Subjects CS3150-A-J101 JapicCTI-163473 Summary Results (JapicCTI)
Esaxerenone
(CS-3150)
MINNEBRO® Healthy Subjects CS3150-A-J107 JapicCTI-152832 Summary Results (JapicCTI)
Efatutazone Discontinued Colorectal Cancer CS7017-A-J111 JapicCTI-101230
Efatutazone Discontinued Non-Smal Cell Lung Cancer CS7017-A-A110 NCT01199068 Tabulated Results (CT.gov)
Efatutazone Discontinued Non-Smal Cell Lung Cancer CS7017-A-A108 NCT01199055 Tabulated Results (CT.gov)
Efatutazone Discontinued Solid Cancer CS7017-A-J107 JapicCTI-090968
Efatutazone Discontinued Lung Cancer CS7017-A-U204 NCT01101334
2009-016083-36
Tabulated Results (CT.gov)
Summary Results (EU-CTIS)
Efatutazone Discontinued Colorectal Cancer CS7017-A-E201 NCT00986440
2008-005848-16
Tabulated Results (CT.gov)
Summary Results (EU-CTIS)
Efatutazone Discontinued Colorectal Cancer CS7017-A-U203 NCT00967616 Tabulated Results (CT.gov)
Efatutazone Discontinued Cancer CS7017-A-U102E NCT00881569 Tabulated Results (CT.gov)
Efatutazone Discontinued Lung Cancer CS7017-A-U202 NCT00806286
2009-013428-22
Tabulated Results (CT.gov)
Efatutazone Discontinued Anaplastic Thyroid Cancer CS7017-A-U103 NCT00603941 Tabulated Results (CT.gov)
Efatutazone Discontinued Neoplasm CS7017-A-U102 NCT00408434 Tabulated Results (CT.gov)
Enbrel BS Discontinued Rheumatoid Arthritis CHS-0214-02 JapicCTI-142621
Enbrel BS Discontinued Rheumatoid Arthritis CHS-0214-05 JapicCTI-152927
Exatecan Mesylate Discontinued Sarcoma CDR0000271889 NCT00055952
Exatecan Mesylate Discontinued Sarcoma CDR0000271888 NCT00055939
Exatecan Mesylate Discontinued Pancreatic Cancer CDR0000068880 NCT00023972
Exatecan Mesylate Discontinued Esophageal Cancer; Gastric Cancer CDR0000068663 NCT00017212
Exatecan Mesylate Discontinued Biliary Cancer CDR0000067736 NCT00005938
Exatecan Mesylate Discontinued Cervical Cancer CDR0000067525 NCT00004866
Exatecan Mesylate Discontinued Brain and Central Nervous System Cancer; Lymphoma; Unspecified Childhood Solid Cancer CDR0000067330 NCT00004212
Exatecan Mesylate Discontinued Liver Cancer CDR0000067329 NCT00004108
Exatecan Mesylate Discontinued Ovarian, Fallopian Tube, or Peritoneal Cancer CDR0000067258 NCT00004060
Exatecan Mesylate Discontinued Hematologic Cancer CDR0000067149 NCT00004047
Exatecan Mesylate Discontinued Breast Cancer CDR0000067148 NCT00004046
Exatecan Mesylate Discontinued Prostate Cancer CDR0000067146 NCT00004045
Exatecan Mesylate Discontinued Pancreatic cancer CDR0000067147 NCT00003951

G

Generic Name / Project Code Trade Name Medical Condition Study Code Access to Study Access to Results and Plain Language Summaries
Ghrelin Discontinued Anorexia SUN11031 (NA3801) JapicCTI-090723
Ghrelin Discontinued Chronic Obstructive Pulmonary Disease ASBI 307 NCT00698828
2007-007725-46
Tabulated Results (CT.gov)
Summary Results (EU-CTIS)

H

Generic Name / Project Code Trade Name Medical Condition Study Code Access to Study Access to Results and Plain Language Summaries
Hydromorphone NARUVEIN® Cancer Pain DS7113-C-J306 JapicCTI-142736 Summary Results (JapicCTI)
Hydromorphone NARUVEIN® Cancer Pain DS7113-C-J305 JapicCTI-142735 Summary Results (JapicCTI)
Hydromorphone NARUSUS® Cancer Pain DS7113-B-J304 JapicCTI-142667 Summary Results (JapicCTI)
Hydromorphone NARUSUS® Cancer Pain DS7113-B-J303 JapicCTI-142666 Summary Results (JapicCTI)
Hydromorphone NARURAPID® Cancer Pain DS7113-A-J302 JapicCTI-132288 Summary Results (JapicCTI)
Hydromorphone NARURAPID® Cancer Pain DS7113-A-J301 JapicCTI-132338 Summary Results (JapicCTI)
Hydromorphone NARURAPID® Cancer Pain DS7113-A-J201 JapicCTI-132166 Summary Results (JapicCTI)
Hydromorphone NARURAPID®; NARUSUS® Healthy Subjects DS7113-A-J102 JapicCTI-132167 Journal Publication

I

Generic Name / Project Code Trade Name Medical Condition Study Code Access to Study Access to Results and Plain Language Summaries
Influenza Vaccine Intranasal   Prevention of Influenza VN0107-A-J301 JapicCTI-163400
 
Influenza Vaccine Adsorbed Influenza Vaccine H5N1 Prevention of Influenza KIBPCI-A-J303 JapicCTI-142554 Summary Results (JapicCTI)
Influenza Vaccine Adsorbed Influenza Vaccine H5N1 Prevention of Influenza KIBPCI-A-J301 JapicCTI-121919 Summary Results (JapicCTI)
Influenza Vaccine Adsorbed Influenza Vaccine H5N1 Prevention of Influenza KIBPCI-A-J302 JapicCTI-121968 Summary Results (JapicCTI)
Influenza Vaccine Adsorbed Influenza Vaccine H5N1 Prevention of Influenza KIBPCI-A-J201 JapicCTI-132190
Summary Results (JapicCTI)
Influenza Vaccine Influenza HA Vaccine Prevention of Influenza VN0104-A-J201 JapicCTI-142587 Summary Results (JapicCTI)
Irinotecan TOPOTECIN® Small Cell Lung Cancer; Non-small Cell Lung Cancer; Cervical Cancer; Ovarian Cancer; Gastric Cancer Observational Study JapicCTI-090946
Irinotecan TOPOTECIN® Colorectal Cancer Observational Study JapicCTI-090945
Irinotecan TOPOTECIN® Colorectal Cancer TOP-003 NCT00284258
JapicCTI-060202
Irinotecan TOPOTECIN® Gastric Cancer TOP-002 JapicCTI-050083 Summary Results (JapicCTI)
Influenza Vaccine Discontinued Prevention of Influenza VN100-A-J301 JapicCTI-142493 Summary Results (JapicCTI)
Influenza Vaccine Discontinued Prevention of Influenza VN100-A-J302 JapicCTI-142613 Summary Results (JapicCTI)
Influenza Vaccine Discontinued Prevention of Influenza VN100-A-J303 JapicCTI-152991 Summary Results (JapicCTI)
Influenza Vaccine Discontinued Prevention of Influenza VN100-A-J101 JapicCTI-132096 Summary Results (JapicCTI)
Ioforminol Discontinued Coronary Angiography GE145-A-J203 JapicCTI-142517
Ioforminol Discontinued Coronary Angiography GE145-A-J202 JapicCTI-142518
Ioforminol Discontinued Coronary Angiography GE145-A-J201 JapicCTI-132391

L

Generic Name / Project Code Trade Name Medical Condition Study Code Access to Study Access to Results and Plain Language Summaries
Laninamivir INAVIR® Influenza CS8958-B-J311 JapicCTI-163398 Summary Results (JapicCTI)
Laninamivir INAVIR® Influenza CS8958-B-J310 JapicCTI-163397 Summary Results (JapicCTI)
Laninamivir INAVIR® Influenza (Prophylaxis) CS8958-A-J309 JapicCTI-142679 Summary Results (JapicCTI)
Laninamivir INAVIR® Influenza (Prophylaxis) CS8958-A-J308 JapicCTI-142678 Summary Results (JapicCTI)
Laninamivir INAVIR® Influenza (Prophylaxis) CS8958-A-J307 JapicCTI-111647 Journal Publication
Laninamivir INAVIR® Influenza CS8958-A-J306 JapicCTI-090941 Summary Results (JapicCTI)
Laninamivir INAVIR® Influenza CS8958-A-J305 JapicCTI-090940 Summary Results (JapicCTI)
Laninamivir INAVIR® Influenza CS8958-A-A202 JapicCTI-090826 Summary Results (JapicCTI)
Laninamivir INAVIR® Influenza CS8958-A-J304 JapicCTI-090814 Summary Results (JapicCTI)
Laninamivir INAVIR® Influenza CS8958-A-J303 JapicCTI-090813 Summary Results (JapicCTI)
Laninamivir INAVIR® Influenza CS8958-A-J302 JapicCTI-090812 Summary Results (JapicCTI)
Laninamivir INAVIR® Influenza CS8958-A-J301 NCT00803595 Tabulated Results (CT.gov)
Laninamivir INAVIR® Influenza CS8958-A-J203 JapicCTI-090811 Summary Results (JapicCTI)
Laninamivir INAVIR® Influenza CS8958-A-J201 JapicCTI-090810 Summary Results (JapicCTI)
Laninamivir INAVIR® Healthy Subjects CS8958-B-J109 JapicCTI-152996 Summary Results (JapicCTI)
Laninamivir INAVIR® Healthy Subjects CS8958-A-J108 JapicCTI-111441 Journal Publication
Levofloxacin CRAVIT® Infections DR3355-B-J305 JapicCTI-121861 Summary Results (JapicCTI)
Levofloxacin CRAVIT® Infections DR3355-B-J304 JapicCTI-121898 Summary Results (JapicCTI)
Levofloxacin CRAVIT® Infections DR3355-B-J303 JapicCTI-121858 Summary Results (JapicCTI)
Levofloxacin CRAVIT® Infections DR3355-B-J302 JapicCTI-121844 Summary Results (JapicCTI)
Levofloxacin CRAVIT® Infections DR3355-B-J301 JapicCTI-121819 Summary Results (JapicCTI)
Levofloxacin CRAVIT® Infections DR3355-60 JapicCTI-070486 Summary Results (JapicCTI)

M

Generic Name / Project Code Trade Name Medical Condition Study Code Access to Study Access to Results and Plain Language Summaries
Measles-Mumps-Rubella Vaccine Prevention of Measles; Mumps; Rubella VN0102-A-J301 JapicCTI-205118
Measles-Mumps-Rubella Vaccine Prevention of Measles; Mumps; Rubella VN0102-A-J302 JapicCTI-205117
Measles-Mumps-Rubella Vaccine Prevention of Measles; Mumps; Rubella VN0102-A-J303 JapicCTI-205114
Measles-Mumps-Rubella Vaccine Prevention of Measles; Mumps; Rubella JVC-001-P12-01 JapicCTI-153031 Summary Results (JapicCTI)
Mirogabalin
(DS-5565)
TARLIGE® Diabetic Peripheral Neuropathic Pain DS5565-A-A315 NCT04094662
Mirogabalin
(DS-5565)
TARLIGE® Central Neuropathic Pain DS5565-A-J314 NCT03901352
JapicCTI-194653
Mirogabalin
(DS-5565)
TARLIGE® Fibromyalgia DS5565-A-U307 NCT02496884
2014-003972-21
Tabulated Results (CT.gov)
Tabulated Results (EU-CTIS)
Mirogabalin
(DS-5565)
TARLIGE® Fibromyalgia DS5565-A-E309 NCT02146430
2013-005161-40
Tabulated Results (CT.gov)
Tabulated Results (EU-CTIS)
Mirogabalin
(DS-5565)
TARLIGE® Fibromyalgia DS5565-A-E311 NCT02187159
2013-005163-10
Tabulated Results (EU-CTIS)
Mirogabalin
(DS-5565)
TARLIGE® Post-herpetic Neuralgia DS5565-A-J304 NCT02318719
JapicCTI-142742
Tabulated Results (CT.gov)
Summary Results (JapicCTI)
Mirogabalin
(DS-5565)
TARLIGE® Renal Impairment; Diabetic Peripheral Neuropathic Pain; Post-herpetic Neuralgia DS5565-A-J313 NCT02607280
JapicCTI-153059
Tabulated Results (CT.gov)
Summary Results (JapicCTI)
Mirogabalin
(DS-5565)
TARLIGE® Pain Associated With Fibromyalgia DS5565-A-E310 NCT02187471
2013-005162-20
Tabulated Results (EU-CTIS)
Mirogabalin
(DS-5565)
TARLIGE® Diabetic Peripheral Neuropathic Pain DS5565-A-J303 NCT02318706
JapicCTI-142741
Tabulated Results (CT.gov)
Summary Results (JapicCTI)
Mirogabalin
(DS-5565)
TARLIGE® Pain Associated with Fibromyalgia DS5565-A-E312 NCT02234583
2013-005164-26
Tabulated Results (CT.gov)
Tabulated Results (EU-CTIS)
Mirogabalin
(DS-5565)
TARLIGE® Diabetic Peripheral Neuropathy DS5565-A-U201 NCT01496365 Tabulated Results (CT.gov)
Mirogabalin
(DS-5565)
TARLIGE® Type 2 Diabetes Mellitus; Diabetic Peripheral Neuropathic Pain DS5565-A-J202 NCT01504412
JapicCTI-111713
Tabulated Results (CT.gov)
Summary Results (JapicCTI)
Mirogabalin
(DS-5565)
TARLIGE® Renal Dysfunction DS5565-A-J115 JapicCTI-132175 Summary Results (JapicCTI)
Mirogabalin
(DS-5565)
TARLIGE® Healthy Subjects DS5565-A-J316 JapicCTI-205156
Mirogabalin
(DS-5565)
TARLIGE® Healthy Subjects DS5565-A-A118 JapicCTI-173680 Summary Results (JapicCTI)
Memantine MEMARY® Alzheimer's Disease SUNY7017-A-J301 JapicCTI-163209
Memantine MEMARY® Alzheimer's Disease SUN Y7017 (IE3701) JapicCTI-121743 Summary Results (JapicCTI)
Memantine MEMARY® Alzheimer's Disease SUN Y7017 (MA3301) JapicCTI-050079 Summary Results (JapicCTI)
Memantine MEMARY® Alzheimer's Disease SUN Y7017 (IE3501) JapicCTI-050078 Summary Results (JapicCTI)
Morphine Sulfate MORPHABOND™️ Baseline Epidemiologic Assessment MORPH-A-U403 NCT04033094
Milademetan Out-licensed Acute Myeloid Leukemia DS3032-A-J104 NCT03671564
JapicCTI-184054
Milademetan Out-licensed Hematological Malignancies DS3032-A-U102 NCT02319369
Milademetan Out-licensed Advanced Solid Cancer; Lymphomas DS3032-A-U101 NCT01877382
Milademetan Out-licensed Solid Cancer; Lymphomas DS3032-A-J103 JapicCTI-142693 Summary Results (JapicCTI)
Milademetan Out-licensed Acute Myeloid Leukemia DS3032-A-U105 NCT03552029
Milademetan Out-licensed Healthy Subjects DS3032-A-U107 NCT03614455
Milademetan Out-licensed Healthy Subjects DS3032-A-U115 NCT03647202

N

Generic Name / Project Code Trade Name Medical Condition Study Code Access to Study Access to Results and Plain Language Summaries
Nafamostat
(DS-2319)
Discontinued Healthy Subjects DS2319-A-J101 jRCT2051200153
Nimotuzumab Discontinued Lung Cancer DE766-A-J303 JapicCTI-132084
Nimotuzumab Discontinued Esophageal Cancer DE766-A-J102 JapicCTI-101319
Nimotuzumab Discontinued Gastric Cancer DE766-A-J202 JapicCTI-090825
Nimotuzumab Discontinued Gastric Cancer DE766-A-J201 JapicCTI-090849

O

Generic Name / Project Code Trade Name Medical Condition Study Code Access to Study Access to Results and Plain Language Summaries
Ofloxacin TARIVID® Infections 8280A-PRT021 NCT00781521
Olmesartan Medoxomil BENICAR®; OLMETEC® Hypertension CS0866-A-U301 NCT00151775
2015-003329-32
Tabulated Results (CT.gov)
Tabulated Results (EU-CTIS)
Olmesartan Medoxomil BENICAR®; OLMETEC® Metabolic Syndrome; Hypertension DSE-866/47 NCT00676845
2007-003131-23
Summary Results (EU-CTIS)
Olmesartan Medoxomil BENICAR®; OLMETEC® Essential Hypertension; Carotid Plaque DSE-OLM-01-09 NCT01132768
2009-013342-92
Olmesartan Medoxomil BENICAR®; OLMETEC® Hypertension 866-447 NCT00185120
Olmesartan Medoxomil BENICAR®; OLMETEC® Metabolic Syndrome; Hypertension DSE-866/46 NCT00891267
2007-003130-41
Summary Results (EU-CTIS)
Olmesartan Medoxomil BENICAR®; OLMETEC® Diabetic Nephropathy; Type 2 Diabetes Mellitus; Proteinuria 149-011/150-008 (ORIENT) NCT00141453
JapicCTI-050027
Tabulated Results (CT.gov)
Olmesartan Medoxomil BENICAR®; OLMETEC® Hypertension CS0866-A-U452 NCT00949884 Tabulated Results (CT.gov)
Olmesartan Medoxomil BENICAR®; OLMETEC® Mild to moderate hypertension SP-OLM-03-05 NCT00311155
2005-004659-36
Tabulated Results (CT.gov)
Summary Results (EU-CTIS)
Olmesartan Medoxomil BENICAR®; OLMETEC® Essential Hypertension; Renal Impairment SE-866/43 NCT00151827
Olmesartan Medoxomil BENICAR®; OLMETEC® Essential Hypertension SS-866/01 NCT00856271
Olmesartan Medoxomil BENICAR®; OLMETEC® Essential Hypertension SS-866 CMB/01 NCT00872586
Olmesartan Medoxomil BENICAR®; OLMETEC® Chronic Glomerulonephritis or Diabetic Nephropathy CS0866-C-J201 NCT00914524
Olmesartan Medoxomil BENICAR®; OLMETEC® Chronic Heart Failure; High Blood B-type (or Brain) Natriuretic Peptide Level DSE-866-45 NCT00679484
2007-003060-22
Summary Results (EU-CTIS)
Olmesartan Medoxomil BENICAR®; OLMETEC® Hypertension CS0866-A-U102 NCT00151814
2015-003328-30
Tabulated Results (CT.gov)
Tabulated Results (EU-CTIS)
Olmesartan Medoxomil BENICAR®; OLMETEC® Hypertension 866-451 NCT00430638 Tabulated Results (CT.gov)
Olmesartan Medoxomil BENICAR®; OLMETEC® Type 2 Diabetes Mellitus; Cardiovascular Disease; Kidney Disease SE-866/44 NCT00185159
2004-000506-52
Summary Results (EU-CTIS)
Olmesartan Medoxomil BENICAR®; OLMETEC® Hypertension OLM004-071 NCT00858702 Tabulated Results (CT.gov)
Olmesartan Medoxomil BENICAR®; OLMETEC® Hypertension 866-450 NCT00412932 Tabulated Results (CT.gov)
Olmesartan Medoxomil BENICAR®; OLMETEC® Hypertension TSP-866/01 NCT00857285 Tabulated Results (CT.gov)
Olmesartan Medoxomil BENICAR®; OLMETEC® Essential Hypertension SPB-OM-0106 NCT00890591 Tabulated Results (CT.gov)
Olmesartan Medoxomil BENICAR®; OLMETEC® Hypertension 866-432 NCT00772499
Olmesartan Medoxomil BENICAR®; OLMETEC® Isolated Systolic Hypertension SE-866/37 NCT00751829
Olmesartan Medoxomil BENICAR®; OLMETEC® Essential Hypertension SE-866/36 NCT00751751
Olmesartan Medoxomil BENICAR®; OLMETEC® Essential Hypertension SP-OLM-01-00 NCT00185172
2005-004659-36
Olmesartan Medoxomil BENICAR®; OLMETEC® Atherosclerosis; Essential Hypertension SE-866/27 NCT00185185
Olmesartan Medoxomil BENICAR®; OLMETEC® Type 2 Diabetes Mellitus; Renal Disease SE-866/29 NCT00362960
Olmesartan Medoxomil BENICAR®; OLMETEC® Atherosclerosis 866-422 AIMS NCT00382213
Olmesartan Medoxomil BENICAR®; OLMETEC® Essential Hypertension 866-440 NCT00185094
Olmesartan Medoxomil BENICAR®; OLMETEC® Healthy Subjects 866-448 NCT00185055
Olmesartan Medoxomil BENICAR®; OLMETEC® Healthy Subjects CS0866-A-U101 2015-003005-41 Tabulated Results (EU-CTIS)
Olmesartan Medoxomil BENICAR®; OLMETEC® Hypertension OMEGA study JapicCTI-050002 Summary Results (JapicCTI)
Olmesartan Medoxomil BENICAR®; OLMETEC® Hypertension PMS-OLM-200801 JapicCTI-101162 Summary Results (JapicCTI)
Olmesartan Medoxomil + Amlodipine AZOR®; SEVIKAR® Hypertension DSE-SEV-02-09 NCT01101009
Olmesartan Medoxomil + Amlodipine AZOR®; SEVIKAR® Hypertension CS8663-404 NCT00791258 Tabulated Results (CT.gov)
Olmesartan Medoxomil + Amlodipine AZOR®; SEVIKAR® Type 2 Diabetes Mellitus; Hypertension CS-8663-403 NCT00654745 Tabulated Results (CT.gov)
Olmesartan Medoxomil + Amlodipine AZOR®; SEVIKAR® Hypertension 8663-402 NCT00527514 Tabulated Results (CT.gov)
Olmesartan Medoxomil + Amlodipine AZOR®; SEVIKAR® Hypertension CS8663-A-U301 NCT00185133
Olmesartan Medoxomil + Amlodipine AZOR®; SEVIKAR® Essential Hypertension CS8663-A-E303 NCT00220233
2005-000450-75
Summary Results (EU-CTIS)
Olmesartan Medoxomil + Amlodipine AZOR®; SEVIKAR® Essential Hypertension CS8663-A-E302 NCT00220220
2005-000447-28
Summary Results (EU-CTIS)
Olmesartan Medoxomil + Amlodipine AZOR®; SEVIKAR® Essential Hypertension DSE-SEV-02-09 2009-012966-30 Summary Results (EU-CTIS)
Olmesartan Medoxomil + Amlodipine AZOR®; SEVIKAR® Healthy Subjects SS8663-03 JapicCTI-111580 Journal Publication
Olmesartan Medoxomil + Amlodipine AZOR®; SEVIKAR® Hypertension SS8663-02 JapicCTI-111581 Journal Publication
Olmesartan Medoxomil + Amlodipine AZOR®; SEVIKAR® Hypertension SS8663-01 JapicCTI-111583 Journal Publication
Olmesartan Medoxomil + Amlodipine + Hydrochlorothiazide TRIBENZOR®; SEVIKAR HCT® Essential Hypertension CS8635-A-E302 NCT00923091
2008-003534-25
Tabulated Results (CT.gov)
Summary Results (EU-CTIS)
Olmesartan Medoxomil + Amlodipine + Hydrochlorothiazide TRIBENZOR®; SEVIKAR HCT® Essential Hypertension CS8635-A-E303 NCT00902538
2008-003535-20
Tabulated Results (CT.gov)
Summary Results (EU-CTIS)
Olmesartan Medoxomil + Amlodipine + Hydrochlorothiazide TRIBENZOR®; SEVIKAR HCT® Hypertension CS8635-A-U301 NCT00649389 Tabulated Results (CT.gov)
Olmesartan Medoxomil + Amlodipine + Hydrochlorothiazide TRIBENZOR®; SEVIKAR HCT® Essential Hypertension CS8635-SIT-11-01 NCT01838850
Olmesartan Medoxomil + Azelnidipine REZALTAS® Hypertension CS0866AZ-A-J301 JapicCTI-060286 Summary Results (JapicCTI)
Olmesartan Medoxomil + Azelnidipine REZALTAS® Hypertension CS0866AZ-A-J302 JapicCTI-060295 Summary Results (JapicCTI)
Olmesartan Medoxomil + Azelnidipine REZALTAS® Hypertension CS0866AZ-A-J303 JapicCTI-070449 Summary Results (JapicCTI)
Olmesartan Medoxomil + Hydrochlorothiazide BENICAR HCT®; OLMETEC PLUS® Type 2 Diabetes Mellitus 866-449 NCT00403481 Tabulated Results (CT.gov)
Olmesartan Medoxomil + Hydrochlorothiazide BENICAR HCT®; OLMETEC PLUS® Hypertension CS866CM-B-E301 NCT00430508
2006-003876-37
Tabulated Results (CT.gov)
Summary Results (EU-CTIS)
Olmesartan Medoxomil + Hydrochlorothiazide BENICAR HCT®; OLMETEC PLUS® Essential Hypertension CS866CM-B-E302 NCT00430950
2006-003877-28
Tabulated Results (CT.gov)
Summary Results (EU-CTIS)
Olmesartan Medoxomil; Olmesartan Medoxomil + Hydrochlorothiazide BENICAR®; OLMETEC®; BENICAR HCT®; OLMETEC PLUS® Essential Hypertension 866-443 NCT00185068
Oxycodone OXYCODONE Healthy Subjects DS5058-C-J106 JapicCTI-173793 Summary Results (JapicCTI)
Oxycodone OXYCODONE Healthy Subjects DS5058-C-J104 JapicCTI-173606 Summary Results (JapicCTI)
Oxycodone OXYCODONE Healthy Subjects DS5058-A-J101 JapicCTI-163475 Summary Results (JapicCTI)
Observational Study N/A Hyper-cholesterolemia; Mixed Dyslipidemia DSE-BMP-01-20 NCT04579367
Observational Study N/A Dyslipidemic; Atherosclerotic Cardiovascular Disease; Hyper-cholesterolemia DSE-HCL-01-19-EU NCT04271280
Observational Study N/A Tenosynovial Giant Cell Tumors DS-ONC-01-15-EU NCT02948088
Observational Study N/A Gastric Cancer; Gastroesophageal Junction Cancer; Colorectal Cancer DS-Screen JapicCTI-163380
Observational Study N/A Nonhemorrhagic Ischemic Stroke ASBI 801 NCT01496885 Tabulated Results (CT.gov)
Observational Study N/A Healthy Subjects (Measure of Tidal Breathing) JapicCTI-153093
Observational Study N/A Venous Thromboembolism DSE-VTE-01-12 DRKS00004795

P

Generic Name / Project Code Trade Name Medical Condition Study Code Access to Study Access to Results and Plain Language Summaries
Patritumab Deruxtecan
(U3-1402)
Non-small Cell Lung Cancer  U31402-A-U103 NCT04676477
jRCT2031200247
Patritumab Deruxtecan
(U3-1402)
Non-small Cell Lung Cancer  U31402-A-U201 NCT04619004
2020-000730-17
jRCT2031200186
Patritumab Deruxtecan
(U3-1402)
Colorectal Cancer U31402-A-U202 NCT04479436
jRCT2031200139
Patritumab Deruxtecan
(U3-1402)
Non-small Cell Lung Cancer U31402-A-U102 NCT03260491
2017-000543-41
JapicCTI-194868
Patritumab Deruxtecan
(U3-1402)
Breast Cancer U31402-A-J101 NCT02980341
JapicCTI-163401
Pexidartinib
(PLX3397)
TURALIO™️ Tenosynovial Giant Cell Tumor PL3397-A-J304 NCT04703322
jRCT2041200074
Pexidartinib
(PLX3397)
TURALIO™️ Tenosynovial Giant Cell Tumor PL3397-A-U401 NCT04635111
Pexidartinib
(PLX3397)
TURALIO™️ Tenosynovial Giant Cell Tumor PL3397-A-A303 NCT04488822
Pexidartinib
(PLX3397)
TURALIO™️ Moderate Hepatic Impairment PL3397-A-U129 NCT04223635 Tabulated Results (CT.gov)
Pexidartinib
(PLX3397)
TURALIO™️ Tenosynovial Giant Cell Tumor; KIT-mutant Tumor; Other Solid Cancer PL3397-A-U126 NCT03291288 Tabulated Results (CT.gov)
Pexidartinib
(PLX3397)
TURALIO™️ Advanced Solid Cancer PL3397-A-A103 NCT02734433 Tabulated Results (CT.gov)
Plain Language Summary
Pexidartinib
(PLX3397)
TURALIO™️ Melanoma; Non-small Cell Lung Cancer; Head and Neck Cancer; Gastrointestinal Stromal Tumor (GIST); Ovarian Cancer PLX108-14 NCT02452424 Tabulated Results (CT.gov)
Plain Language Summary
Pexidartinib
(PLX3397)
TURALIO™️ Melanoma PLX108-13 NCT02975700 Tabulated Results (CT.gov)
Plain Language Summary
Pexidartinib
(PLX3397)
TURALIO™️ Pigmented Villonodular Synovitis; Giant Cell Tumor of the Tendon Sheath PLX108-10 NCT02371369
2014-000148-14
Tabulated Results (CT.gov)
Tabulated Results (EU-CTIS)
Plain Language Summary
Pexidartinib
(PLX3397)
TURALIO™️ Melanoma PLX108-09 NCT01826448 Tabulated Results (CT.gov)
Plain Language Summary
Pexidartinib
(PLX3397)
TURALIO™️ Glioblastoma PLX108-08 NCT01790503 Tabulated Results (CT.gov)
Plain Language Summary
Pexidartinib
(PLX3397)
TURALIO™️ Solid Cancer PLX108-07 NCT01525602 Tabulated Results (CT.gov)
Plain Language Summary
Pexidartinib
(PLX3397)
TURALIO™️ Prostate Cancer PLX108-06 NCT01499043 Tabulated Results (CT.gov)
Plain Language Summary
Pexidartinib
(PLX3397)
TURALIO™️ Acute Myeloid Leukemia PLX108-05 NCT01349049 Tabulated Results (CT.gov)
Plain Language Summary
Pexidartinib
(PLX3397)
TURALIO™️ Glioblastoma PLX108-04 NCT01349036 Tabulated Results (CT.gov)
Plain Language Summary
Pexidartinib
(PLX3397)
TURALIO™️ Hodgkin Lymphoma PLX108-03 NCT01217229 Tabulated Results (CT.gov)
Plain Language Summary
Pexidartinib
(PLX3397)
TURALIO™️ Solid Cancer PLX108-01 NCT01004861 Tabulated Results (CT.gov)
Plain Language Summary
Pexidartinib
(PLX3397)
TURALIO™️ Healthy Subjects PL3397-A-U128 NCT03901313 Tabulated Results (CT.gov)
Pexidartinib
(PLX3397)
TURALIO™️ Healthy Subjects PL3397-A-U122 NCT03138759 Plain Language Summary
Prasugrel
(CS-747)
EFFIENT® Acute Coronary Syndrome CS747S-B-A4003 NCT03672097
Prasugrel
(CS-747)
EFFIENT® Thrombotic Stroke CS747S-A-J305 JapicCTI-184141
Prasugrel
(CS-747)
EFFIENT® Cerebrovascular Accident CS747S-A-J304 JapicCTI-121901
Prasugrel
(CS-747)
EFFIENT® Cerebrovascular Accident CS0747S-A-J303 JapicCTI-111582
Prasugrel
(CS-747)
EFFIENT® Coronary Artery Disease CS0747S-B-J302 JapicCTI-111550 Journal Publication
Prasugrel
(CS-747)
EFFIENT® Acute Coronary Syndrome CS0747S-B-J301 JapicCTI-101339 Journal Publication
Prasugrel
(CS-747)
EFFIENT® Stroke CS0747S-A-J203 JapicCTI-101044
Prasugrel
(CS-747)
EFFIENT® Coronary Artery Disease CS747S-B-U4003 NCT01587651
2011-004064-29
Tabulated Results (CT.gov)
Summary Results (EU-CTIS)
Prasugrel
(CS-747)
EFFIENT® Coronary Artery Disease CS747S-B-U4002 NCT01260584 Tabulated Results (CT.gov)
Prasugrel
(CS-747)
EFFIENT® Coronary Artery Disease CS747S-B-U4001 NCT01014624 Tabulated Results (CT.gov)
Perflubutane SONAZOID® Prostate Cancer DD723-B-J301 JapicCTI-101308 Summary Results (JapicCTI)
Perflubutane SONAZOID® Breast Cancer DD723-B-J302 JapicCTI-101287 Journal Publication
Perflubutane SONAZOID® Prostate Cancer DD723-B-J201 JapicCTI-090893 Summary Results (JapicCTI)
Perflubutane SONAZOID® Breast Cancer DD723-B-J202 JapicCTI-090894 Journal Publication
Pravastatin MEVALOTIN® Hyperlipidemia APPROACH-J JapicCTI-080534
Pactimibe Sulfate Discontinued Atherosclerosis; Heterozygous Familial Hyper-cholesterolemia 505-205 NCT00151788
Pactimibe Sulfate Discontinued Coronary Artery Disease 505-202 NCT00185042
Pactimibe Sulfate Discontinued Atherosclerosis SE-505/14 NCT00185146
Patritumab Discontinued Head and Neck Cancer U31287-A-U203 NCT02633800
2015-002222-40
Tabulated Results (EU-CTIS)
Patritumab Discontinued Lung Cancer U31287-A-J107 JapicCTI-152841
Patritumab Discontinued Head and Neck Cancer U31287-A-U106 NCT02350712
2014-002445-22
Patritumab Discontinued Lung Cancer; Non-small Cell Lung Cancer U31287-A-U301 NCT02134015
2013-004371-12
Tabulated Results (CT.gov)
Summary Results (EU-CTIS)
Patritumab Discontinued Solid Cancer U31287-A-U105 NCT01957280
Patritumab Discontinued Metastatic Breast Cancer U3-1287-A-U202 NCT01512199
Patritumab Discontinued Lung Cancer U31287-A-U201 NCT01211483
2010-021082-74
Tabulated Results (CT.gov)
Tabulated Results (EU-CTIS)
Patritumab Discontinued Non-small Cell Lung Cancer U31287-A-U201E 2013-000104-42 Tabulated Results (EU-CTIS)
Patritumab Discontinued Breast Cancer U31287-A-J103 JapicCTI-121772
Patritumab Discontinued Lung Cancer U31287-A-J102 JapicCTI-111506
Patritumab Discontinued Solid Cancer U31287-A-J101 JapicCTI-101262
Piclozotan Discontinued Parkinson's Disease ASBI-501 NCT00623363 Tabulated Results (CT.gov)
Piclozotan Discontinued Acute Ischemic Stroke SPI-103 NCT00272909
2004-002437-39
Summary Results (EU-CTIS)

Q

Generic Name / Project Code Trade Name Medical Condition Study Code Access to Study Access to Results and Plain Language Summaries
Quizartinib
(AC220)
VANFLYTA® Acute Myeloid Leukemia AC220-A-U202 NCT03793478
Quizartinib
(AC220)
VANFLYTA® Acute Myeloid Leukemia AC220-A-A103 NCT03723681
Quizartinib
(AC220)
VANFLYTA® Acute Myeloid Leukemia; Leukemia AC220-A-U302 NCT02668653
2015-004856-24
JapicCTI-173667
Quizartinib
(AC220)
VANFLYTA® Acute Myeloid Leukemia AC220-A-J201 NCT02984995
JapicCTI-163441
Tabulated Results (CT.gov)
Summary Results (JapicCTI)
Plain Language Summary
Plain Language Summary (JP)
Quizartinib
(AC220)
VANFLYTA® Acute Myeloid Leukemia AC220-A-J102 NCT02834390
JapicCTI-163309
Tabulated Results (CT.gov)
Summary Results (JapicCTI)
Plain Language Summary
Plain Language Summary (JP)
Quizartinib
(AC220)
VANFLYTA® Relapsed or Refactory Acute Myeloid Leukemia AC220-A-J101 NCT02675478
JapicCTI-163142
Summary Results (JapicCTI)
Plain Language Summary
Plain Language Summary (JP)
Quizartinib
(AC220)
VANFLYTA® Acute Myeloid Leukemia AC220-007 NCT02039726
2013-004890-28
Tabulated Results (CT.gov)
Tabulated Results (EU-CTIS)
Plain Language Summary
Quizartinib
(AC220)
VANFLYTA® Acute Myeloid Leukemia 2689-CL-2004 NCT01565668
2011-005408-13
Tabulated Results (CT.gov)
Tabulated Results (EU-CTIS)
Plain Language Summary
Quizartinib
(AC220)
VANFLYTA® Acute Myeloid Leukemia 2689-CL-0011 NCT01468467 Plain Language Summary
Quizartinib
(AC220)
VANFLYTA® Acute Myeloid Leukemia 2689-CL-0005 NCT01390337
Quizartinib
(AC220)
VANFLYTA® Solid Cancer AC220-004 NCT01049893
Quizartinib
(AC220)
VANFLYTA® Acute Myeloid Leukemia AC220-002 NCT00989261
2009-013093-41
Tabulated Results (CT.gov)
Tabulated Results (EU-CTIS)
Plain Language Summary
Quizartinib
(AC220)
VANFLYTA® Acute Myeloid Leukemia CP0001 NCT00462761 Tabulated Results (CT.gov)
Plain Language Summary
Quizartinib
(AC220)
VANFLYTA® Moderate Hepatic Impairment AC220-A-U105 NCT04473664
Quizartinib
(AC220)
VANFLYTA® Healthy Subjects AC220-A-U107 NCT04796831
Quizartinib
(AC220)
VANFLYTA® Healthy Subjects AC220-A-U106 NCT04459598
Quizartinib
(AC220)
VANFLYTA® Healthy Subjects AC220-A-U104 NCT04459585 Tabulated Results (CT.gov)

R

Generic Name / Project Code Trade Name Medical Condition Study Code Access to Study Access to Results and Plain Language Summaries
Renadirsen
(DS-5141)
Duchenne Muscular Dystrophy DS5141-A-J201 NCT04433234
JapicCTI-205321
Renadirsen
(DS-5141)
Duchenne Muscular Dystrophy DS5141-A-J101 NCT02667483
JapicCTI-153072
RS Virus Vaccine
(VN-0200)
Prevention of Respiratory Syncytial Virus Infection VN0200-A-J101 NCT04914520
jRCT2031210069
Rifampicin RIFADIN® Healthy Subjects RIFADI-A-J101 JapicCTI-173675
Rivoglitazone Discontinued Type 2 Diabetes Mellitus CS011-A-U302 NCT00571519 Tabulated Results (CT.gov)
Rivoglitazone Discontinued Type 2 Diabetes Mellitus CS0011-203 NCT00143520
Rivoglitazone Discontinued Type 2 Diabetes Mellitus CS0011-A-U301 NCT00484198
2006-005047-28
Tabulated Results (CT.gov)
Summary Results (EU-CTIS)
Rivoglitazone Discontinued Type 2 Diabetes Mellitus CS011-A-J204 NCT00575471
JapicCTI-070424
Rivoglitazone Discontinued Type 2 Diabetes Mellitus CS011-A-J205 NCT00575874
Rivoglitazone Discontinued Type II Diabetes Mellitus CS0011-A-U302 2007-005263-97 Summary Results (EU-CTIS)

S

Generic Name / Project Code Trade Name Medical Condition Study Code Access to Study Access to Results and Plain Language Summaries
Sitafloxacin GRACE BIT® Infections DU6859-A-J301 JapicCTI-090731 Summary Results (JapicCTI)
Sitafloxacin GRACE BIT® Infections DU6859a-49 JapicCTI-050062
Sitafloxacin GRACE BIT® Infections DU6859a-43 JapicCTI-050063
Sitafloxacin GRACE BIT® Infections DU6859a-48 JapicCTI-050064
Sitafloxacin GRACE BIT® Infections DU6859a-47 JapicCTI-050065
Sitafloxacin GRACE BIT® Infections DU6859a-45 JapicCTI-050066
Sitafloxacin GRACE BIT® Infections DU6859a-44 JapicCTI-050067
Sitafloxacin GRACE BIT® Infections DU6859a-42 JapicCTI-050068
Sitafloxacin GRACE BIT® Infections DU6859a-46 JapicCTI-050069
Soblidotin Discontinued Soft Tissue Sarcoma CDR0000310138 NCT00064220
Soblidotin Discontinued Non-small Cell Lung Cancer CDR0000301749 NCT00061854
SUN13834 Discontinued Atopic Dermatitis ASBI 404 NCT00717769
SUN13837 Discontinued Acute Spinal Cord Injury ASBI 603 NCT01502631
2012-004373-80
Tabulated Results (CT.gov)
Tabulated Results (EU-CTIS)
SUN13837 Discontinued Stroke ASBI 802 NCT02258880
Sodium Hyaluronate N/A Hip Osteoarthritis ADA 2003-01 NCT00330135
Spironolactone N/A Diabetes N/A JapicCTI-132140

T

Generic Name / Project Code Trade Name Medical Condition Study Code Access to Study Access to Results and Plain Language Summaries
Trastuzumab Deruxtecan
(DS-8201)
ENHERTU® Breast Cancer DESTINY-Breast12
D9673C00007
jRCT2031210182
Trastuzumab Deruxtecan
(DS-8201)
ENHERTU® Solid Cancer DESTINY-PanTumor01
D967MC00001
jRCT2031210132
Trastuzumab Deruxtecan
(DS-8201)
ENHERTU® Breast Cancer DESTINY-Breast09
D967UC00001
jRCT2031210130
Trastuzumab Deruxtecan
(DS-8201)
ENHERTU® Colorectal Cancer DESTINY-CRC02
DS8201-A-U207
NCT04744831
jRCT2051200124
Trastuzumab Deruxtecan
(DS-8201)
ENHERTU® Gastric Cancer; Gastroesophageal Junction Adenocarcinoma DESTINY-Gastric04
DS8201-A-U306
NCT04704934
jRCT2031200369
Trastuzumab Deruxtecan
(DS-8201)
ENHERTU® Non-small Cell Lung Cancer DESTINY-LUNG02
DS8201-A-U206
NCT04644237
jRCT2061200038
Trastuzumab Deruxtecan
(DS-8201)
ENHERTU® Breast Cancer DESTINY-Breast05
DS8201-A-U305
NCT04622319
jRCT2061200033
Trastuzumab Deruxtecan
(DS-8201)
ENHERTU® Breast Cancer DESTINY-Breast06
D9670C00001
jRCT2061200028
Trastuzumab Deruxtecan
(DS-8201)
ENHERTU® Gastric Cancer DESTINY-Gastric03
D967LC00001
jRCT2031200203
Trastuzumab Deruxtecan
(DS-8201)
ENHERTU® Breast Cancer; Non-small Cell Lung Cancer DS8201-A-U106 NCT04042701
2018-002489-38
Trastuzumab Deruxtecan
(DS-8201)
ENHERTU® Gastric Cancer DESTINY-Gastric02
DS8201-A-U205
NCT04014075
2019-001512-34
Trastuzumab Deruxtecan
(DS-8201)
ENHERTU® Breast Cancer DESTINY-Breast04
DS8201-A-U303
NCT03734029
JapicCTI-184223
Trastuzumab Deruxtecan
(DS-8201)
ENHERTU® Breast Cancer DESTINY-Breast03
DS8201-A-U302
NCT03529110
JapicCTI-183976
Trastuzumab Deruxtecan
(DS-8201)
ENHERTU® Breast Cancer DESTINY-Breast02
DS8201-A-U301
NCT03523585
JapicCTI-184017
Trastuzumab Deruxtecan
(DS-8201)
ENHERTU® Breast Cancer; Urothelial Cancer DS8201-A-U105 NCT03523572
Trastuzumab Deruxtecan
(DS-8201)
ENHERTU® Non-small Cell Lung Cancer DESTINY-Lung01
DS8201-A-U204
NCT03505710
JapicCTI-183916
Trastuzumab Deruxtecan
(DS-8201)
ENHERTU® Colorectal Cancer DESTINY-CRC01
DS8201-A-J203
NCT03384940
2017-003466-28
JapicCTI-173808
Tabulated Results (CT.gov)
Tabulated Results (EU-CTIS)
Trastuzumab Deruxtecan
(DS-8201)
ENHERTU® Neoplasm Metastasis DS8201-A-A104 NCT03383692
JapicCTI-173790
Tabulated Results (CT.gov)
Trastuzumab Deruxtecan
(DS-8201)
ENHERTU® Gastric Cancer; Breast Cancer DS8201-A-A103 NCT03368196 Tabulated Results (CT.gov)
Trastuzumab Deruxtecan
(DS-8201)
ENHERTU® Breast Cancer DS8201-A-J102 NCT03366428
JapicCTI-173791
Tabulated Results (CT.gov)
Trastuzumab Deruxtecan
(DS-8201)
ENHERTU® Gastric Cancer; Gastroesophageal Junction Adenocarcinoma DS8201-C-J4001 JapicCTI-205234 Summary Results (JapicCTI)
Trastuzumab Deruxtecan
(DS-8201)
ENHERTU® Gastric Cancer; Gastroesophageal Junction Adenocarcinoma DESTINY-Gastric01
DS8201-A-J202
NCT03329690
JapicCTI-173727
Tabulated Results (CT.gov)
Trastuzumab Deruxtecan
(DS-8201)
ENHERTU® Breast Cancer DESTINY-Breast01
DS8201-A-U201
NCT03248492
2016-004986-18
JapicCTI-173693
Tabulated Results (CT.gov)
Tabulated Results (EU-CTIS)
Trastuzumab Deruxtecan
(DS-8201)
ENHERTU® Advanced Solid Malignant Tumors DS8201-A-J101 NCT02564900
JapicCTI-152978
Tabulated Results (CT.gov)
Tetravalent Combination Vaccine SQUAREKIDS® Prevention of Pertussis; Diphtheria; Tetanus; Poliomyelitis Infection DD687-A-J301 JapicCTI-101350 Summary Results (JapicCTI)
Tetravalent Combination Vaccine SQUAREKIDS® Prevention of Pertussis; Diphtheria; Tetanus; Poliomyelitis Infection DD687-A-J201 JapicCTI-090931 Summary Results (JapicCTI)
Tigatuzumab Discontinued Liver Cancer CS1008-A-U204 NCT01033240
JapicCTI-101138
Tigatuzumab Discontinued Metastatic Colorectal Cancer CS1008-A-U105 NCT01124630
Tigatuzumab Discontinued Ovarian Cancer CS1008-A-U205 NCT00945191 Tabulated Results (CT.gov)
Tigatuzumab Discontinued Non-small Cell Lung Cancer CS1008-A-E202 NCT00991796
2007-004574-11
Summary Results (EU-CTIS)
Tigatuzumab Discontinued Colorectal Cancer CS1008-A-E203 NCT00969033
2007-005675-34
Summary Results (EU-CTIS)
Tigatuzumab Discontinued Pancreatic Cancer CS1008-A-U201 NCT00521404 Tabulated Results (CT.gov)
Tigatuzumab Discontinued Solid Cancer; Lymphomas CS1008-A-U101 NCT00320827
Tigatuzumab Discontinued Solid Cancer CS1008-A-J104 JapicCTI-090892
Tivantinib Discontinued Inoperable Hepatocellular Carcinoma ARQ197-A-U303 NCT01755767
2012-003308-10
Tabulated Results (CT.gov)
Tabulated Results (EU-CTIS)
Tivantinib Discontinued Non-squamous, Non-small Cell Lung Cancer ARQ197-A-U302 NCT01244191
2010-022365-10
Tivantinib Discontinued Solid Cancer; Hepatic Impairment ARQ197-A-U160 NCT02150733
Tivantinib Discontinued Colorectal Cancer ARQ197-A-U252 NCT01075048
2009-016025-34
Tabulated Results (CT.gov)
Tabulated Results (EU-CTIS)
Tivantinib Discontinued Solid Cancer ARQ197-A-U158 NCT01517399
Tivantinib Discontinued Cancer ARQ197-A-U159 NCT01699061
Tivantinib Discontinued Non-CNS Germ Cell Tumors ARQ197-A-U251 NCT01055067
2009-015400-26
Tabulated Results (CT.gov)
Summary Results (EU-CTIS)
Tivantinib Discontinued Solid Cancer ARQ197-A-U157 NCT01149720

U

Generic Name / Project Code Trade Name Medical Condition Study Code Access to Study Access to Results and Plain Language Summaries
U3-1565 Discontinued Advanced Solid Malignant Tumors; Advanced Ovarian Cancer U31565-A-U101 NCT01290471
U3-1565 Discontinued Solid Cancer U31565-A-J102 JapicCTI-111484
U3-1784 Discontinued Advanced Solid Cancer; Hepatocellular Cancer U31784-A-E101 NCT02690350

V

Generic Name / Project Code Trade Name Medical Condition Study Code Access to Study Access to Results and Plain Language Summaries
Valemetostat
(DS-3201)
Peripheral T-Cell Lymphoma, Adult T-Cell Leukemia/Lymphoma DS3201-A-U202 NCT04703192
jRCT2071200095
Valemetostat
(DS-3201)
Hepatic Impairment DS3201-A-U106 NCT04276662
Valemetostat
(DS-3201)
Adult T-cell Leukemia/Lymphoma DS3201-A-J201 NCT04102150
JapicCTI-194964
Valemetostat
(DS-3201)
Acute Myelogenous Leukemia; Acute Lymphocytic Leukemia DS3201-A-U102 NCT03110354
Valemetostat
(DS-3201)
Non-hodgkin Lymphoma DS3201-A-J101 NCT02732275
JapicCTI-163173
Valemetostat
(DS-3201)
Healthy Subjects DS3201-A-J109 jRCT2071200043
Valemetostat
(DS-3201)
Healthy Subjects DS3201-A-J107 JapicCTI-205338
Valemetostat
(DS-3201)
Healthy Subjects DS3201-A-J104 JapicCTI-183902
Valemetostat
(DS-3201)
Healthy Subjects DS3201-A-J103 JapicCTI-173804